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Abstract: During the last decade, the application of nanotechnologies for anticancer drug 
delivery has been extensively explored, hoping to improve the efﬁ  cacy and to reduce side 
effects of chemotherapy. The present review is dedicated to a certain kind of anticancer drug 
nanovectors developed to target tumors with the help of an external magnetic ﬁ  eld. More par-
ticularly, this work treats anticancer drug nanoformulations based on superparamagnetic iron 
oxide nanoparticles coated with biocompatible polymers. The major purpose is to focus on the 
speciﬁ  c requirements and technological difﬁ  culties related to controlled delivery of antitumoral 
agents. We attempt to state the problem and its possible perspectives by considering the three 
major constituents of the magnetic therapeutic vectors: iron oxide nanoparticles, polymeric 
coating and anticancer drug.
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Introduction
Nanosciences and nanotechnologies form a growing strategic sector with enormous 
economic potential: “small is big business” (Maliksi 2006). Nanostructures and nano-
systems developed include macromolecules as for example DNA, colloid particles, 
macromolecular assemblies, or even viruses (Emerich and Thanos 2005). Nanosystems 
are governed by surface effects such as hydrophobic interactions, hydrogen bonding, 
ionic bonding or repulsion, covalent bonding.
There is an enormous potential for nanotechnology applied to drug delivery (Kreuter 
2004; Whelan and Mayenne 2006). The vehicle might be a functionalized nanoparticle 
which contains the therapeutic agent and is capable of targeting speciﬁ  c diseased cells 
or organs. Efﬁ  cient drug targeting is mainly explored in the ﬁ  eld of cancer treatment. 
As cancer cells tend to develop multidrug resistance (Baird and Kaye 2003), and the 
serious side effects encountered limit the efﬁ  cacy of chemotherapy (Alexiou et al 
2005), the search for alternative treatments is currently one of the most active areas 
of cancer research (Sachdeva 1998). 
A number of different targeting strategies for cancer therapy have been compre-
hensively reviewed in many publications (Sachdeva 1998; Begent 1999). One rational 
approach involves conjugating cancer chemotherapeutics with ligands speciﬁ  c to the 
cancer cell surface (antibodies or small molecules) in the hope of promoting their 
localization in tumors (Sachdeva 1998; Huang and Oliff 2001). Another approach is 
magnetic drug targeting: magnetoliposomes (De Cuyper and Joniau 1988) or mag-
netic polymer particles (Gupta and Gupta 2005) carrying active molecules represent 
an attractive tool since they allow one to concentrate the drug at a deﬁ  ned target site 
by local application of an external magnetic ﬁ  eld. Nanoparticles of iron oxides, in 
particular magnetite and maghemite, have been shown to offer potential applications 
because of their unique magnetic properties and low toxicity (Pulfer and Gallo 2000; 
Lübbe et al 2001, 2003). International Journal of Nanomedicine 2007:2(4) 542
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The purpose of our article is to focus on the speciﬁ  c 
requirements and the most recent developments related to the 
use of iron oxide nanoparticles for magnetically controlled 
delivery of anticancer drugs. The optimization of critical 
parameters makes the development of magnetic vectors 
of anticancer drugs a multidisciplinary challenge. Indeed, 
the success of this optimization depends not only on novel 
protocols of particle preparation but also on appropriate 
methods of physico-chemical characterization and biological 
evaluation in vitro and in vivo. We attempt to illustrate the 
state of the problem and possible perspectives by considering 
the three major constituents of the nanoparticular magnetic 
vectors: iron oxide nanoparticles, polymeric coating and 
anticancer drugs.
Principle, challenges and limits 
of magnetic drug targeting
The principle of magnetic drug targeting is relatively simple: 
after intravascular injection (Figure 1), magnetic nanopar-
ticles can be transported by the blood circulation and concen-
trated at the tumor with the aid of a magnetic ﬁ  eld applied at 
the affected zone (Lübbe et al 2003). 
Iron oxide particles with diameters below ~30–40 nm are 
of particular interest because they exhibit superparamagnetic 
behavior (Bean and Livingstone 1959). This means that 
once the magnetic ﬁ  eld is removed, they do not retain any 
magnetization (no hysteresis). Superparamagnetic iron oxide 
nanoparticles are already used as contrast media in magnetic 
resonance imaging, and their low toxicity has been demon-
strated for a long time (Neuberger et al 2005).
The iron oxide nanoparticles constitute the core of the 
ﬁ  nal forms of therapeutic nanovectors. From a physico-
chemical point of view, the main objective in the prepara-
tion of magnetic nanoparticles consists in a strict control of 
particle size and colloid stability/dispersibility under physi-
ological conditions. These properties can be modulated by 
coating the particles in two different ways: either the iron 
oxide nanoparticles are physically incorporated in a poly-
mer matrix, or their surface is functionalized with polymer 
molecules (Figure 2). As for the drug, it can be dispersed 
in the polymer matrix, chemically bound to the polymer, or 
directly attached to the iron oxide surface.
After coating, the particle size is increased, but it 
still should remain in the sub-micron range. In this case, 
they will not block vessels and capillaries and thus avoid 
embolization (Alexiou et al 2005). Moreover, size and 
surface of resulting particles are determinant with respect 
to pharmacokinetics in vivo, where major limitations are 
quick blood clearance and non-speciﬁ  c uptake by mac-
rophages. To maximize circulation times and targeting 
external 
magnetic field 
injectable 
suspension of 
nanovectors  tumor target 
Figure 1 Principle of magnetic drug targeting.International Journal of Nanomedicine 2007:2(4) 543
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ability, the optimal size should be less than 100 nm in 
diameter and the surface should be hydrophilic (Bazile et 
al 1995; Storm et al 1995). Ideally, these properties should 
render the particles “furtive”, which means that they are not 
cleared by the reticulo-endothelial system. In addition to 
biocompatibility, the coating should regulate drug loading 
rates and release kinetics. 
Once at the target site, the drug is released from the mag-
netic carrier creating a high local concentration in the tumor 
tissue while minimizing the amount of the drug throughout 
the rest of the body (Lübbe et al 2001). However, this implies 
that the magnetic ﬁ  eld must be applied long enough for the 
drug delivery. The magnet must create a sufﬁ  ciently strong 
magnetic ﬁ  eld to retain nanoparticles at the desired site. The 
success of the method depends on the competitive forces 
between the external magnetic ﬁ  eld and blood ﬂ  ow pressure 
in the arteries and capillaries. Another problem is the depth 
of the target site because the strength of the magnetic ﬁ  eld 
decreases with distance. This implies that one can use this 
technique only in the case of solid tumors close to the surface 
of the body (Pulfer and Gallo 2000). 
First clinical trials
Since 1996, Lübbe performed clinical trials for the treatment 
of breast cancer by magnetic carriers of epirubicin (Lübbe, 
Bergemann, Riess et al 1996). These trials followed pre-
clinical studies (Lübbe, Bergemann, Huhnt et al 1996) that 
documented tolerance and efﬁ  cacy. In the ﬁ  rst trials, epiru-
bicin was ionically bound to a modiﬁ  ed carbohydrate layer 
on iron oxide nanoparticles. The authors clearly observed 
the accumulation of nanoparticles in the target area after 
exposure to the magnetic ﬁ  eld. However, the drug release 
was rather dependent on variable physiological parameters 
(Lübbe et al 2001). Thus, technological improvements were 
necessary to make this treatment more effective. Neverthe-
less, the feasibility of the technique was demonstrated, and 
these results were encouraging for many researchers all over 
the world.
Synthesis of superparamagnetic 
iron oxide nanoparticles
Magnetite (Fe3O4) is a common magnetic oxide that has a 
cubic inverse spinel structure (Tron et al 2000). The most 
common method to prepare magnetite nanoparticles consists 
in mixing solutions of FeCl3 and FeCl2, followed by precipita-
tion of magnetite by addition of a base (Massart 1981). Fe3O4 
nanoparticles may then be superﬁ  cially oxidized to the more 
stable maghemite (γ-Fe2O3) by addition of ferric nitrate to the 
colloidal suspension (Fauconnier et al 1999). Size, shape and 
composition of iron oxide nanoparticles depend on the operat-
ing conditions (pH, nature of the base, Fe2+ and Fe3+ ratio....). 
The content of magnetite and maghemite in these nanoparticles 
can be estimated by techniques such as Mössbauer spectros-
copy (Muller et al 1999) and X-ray diffraction (Lottichi et al 
1998). Recently, we have reported a possibility to deduce the 
magnetite/maghemite ratio in the solid phase of ferroﬂ  uids from 
Raman spectra (Chourpa et al 2005), using the ratio of their 
respective characteristic vibrational bands (671 cm−1/721 cm−1). 
It has also been observed that exposure to oxygen and elevated 
temperatures favored the formation in the ferroﬂ  uids of undesir-
able species like antiferromagnetic hematite.
According to transmission electron microscopy (TEM) 
data (Figure 3a), the iron oxide nanocrystals are nearly 
spherical and their size is most often described in the literature 
(a) (b)
Figure 2 Schematic representation of the coating of iron oxide nanoparticles with polymers via encapsulation (a) or via surface treatment (b). In this latter case, a polymer 
layer may form around individual iron oxide particles or around aggregates. International Journal of Nanomedicine 2007:2(4) 544
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to be within limits of 6–12 nm. As we mentioned above, the 
iron oxide nanoparticles constitute the nucleus of the ﬁ  nal 
nanovector which will necessarily be much bigger. 
Surface properties of iron 
oxide nanoparticles in colloidal 
suspensions
The iron oxide nanoparticles can be dispersed in suitable 
solvents to form homogenous suspensions called ferroﬂ  uids 
or magnetic ﬂ  uids. They present a very interesting amphoteric 
character (Figure 4) due to the presence of hydroxyl groups at 
their surface (Fauconnier et al 1999). Because the stability of 
an aqueous ferroﬂ  uid is mainly due to electrostatic repulsion 
between charged particles, they ﬂ  occulate around the point 
of zero charge (PZC, established around pH 7). Typically, 
the iron oxide nanoparticles are used as cationic ferroﬂ  uids, 
which means that the particle surface is positively charged 
and accompanied by anionic counterions (usually nitrates). 
A PZC close to physiological pH should not necessarily 
be considered an inconvenient, as the particles still have to 
be coated before injection. Thus, the iron oxide nanoparticle 
is just a precursor, and its surface properties need only be 
compatible with coating and drug loading. 
As the nanoparticles have large surface area/volume 
ratios, they tend to adsorb plasma proteins and agglomerate 
in vivo. As a result, without coating the ferrite nanoparticles 
are rapidly cleared by macrophages in the reticulo-endothelial 
system.
As we noted above, one possibility of coating is to 
encapsulate the magnetic particles in a solid polymer matrix 
(Figures 2a and 3b). Alternatively, the hydroxyl groups at the 
surface of iron oxide nanoparticles can be used to directly 
anchor active molecules or polymers. To enrich the choice 
of possible reactions, one can use silanes (Figure 4 insert) 
as coupling intermediates : silanes form Fe-O-Si bonds with 
the particle surface and offer on their opposite end functional 
groups (amines, thiols) that can interact with therapeuti-
cal agents, biologically relevant ligands and polymers (Xu 
et al 1999).
Association of iron oxide 
nanoparticles with pharmaceutical 
polymers by encapsulation
In this case, the objective is to formulate multi-functional 
nanoparticular carrier systems with magnetic material in a 
solid polymer matrix (Häfeli 2004). An important challenge 
in the preparation of magnetic polymer particles, especially 
for drug targeting application, is that the magnetite content 
of the polymer particles should be large enough to permit 
magnetic guidance and delivery of these magnetic particles to 
the target site. Actually, it seems difﬁ  cult to conclude about 
the minimum magnetic content required.
Among a wide variety of synthetic biodegradable 
polymers, only a few are biocompatible and commonly 
used to manufacture polymeric nanoparticles for medical 
applications. They include poly(alkylcyanoacrylates), 
Figure 3 TEM photomicrograph of cationic iron oxide nanoparticles (a), TEM 
photomicrograph of iron oxide nanoparticles encapsulated in PLGA polymer (b).
Both samples were prepared in our laboratory according to the methods described 
previously (Chourpa et al 2005; Ngaboni et al 2005).
(a) 
400 nm 
(b) 
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poly(methylidene malonate), polyanhydrides, polyor-
thoesters and polyesters such as poly(lactic acid), 
poly(glycolic acid), poly(ε-caprolactone) and their copo-
lymers (Barratt 2000).
Deﬁ  ned spherical magnetic microspheres were made 
for the ﬁ  rst time at the end of the 1970s by Widder et al 
(1979). They engineered magnetic albumin microspheres 
containing doxorubicin at low doses and demonstrated 
their utilitity in an animal tumor model (Widder et al 1980, 
1983). However, these albumin particles were generally not 
smaller than 1 μm which precludes intravenous adminis-
tration. In addition, albumin has the disadvantage of pos-
sibly provoking an immune response, so interest has been 
progressively focused on magnetite particles covered with 
dextranes and/or synthetic polymers. Ibrahim described 
for the ﬁ  rst time the preparation of polyalkylcyanoacrylate 
nanoparticles loaded with magnetite and an anticancer 
drug, dactinomycin (Ibrahim et al 1982). Magnetic poly-
alkylcyanoacrylate nanoparticles were prepared by anionic 
polymerization of the monomer (isobutylcyanoacrylate) in 
the presence of magnetite nanoparticles of between 10 and 
50 nm. Final vectors included co-encapsulated dactinomy-
cin drug and had a diameter smaller than 0.3 μm. These 
nanovectors responded to a magnetic ﬁ  eld after intravenous 
administration in mice. A few years later, Hung prepared 
polymer-coated submicron magnetic nanoparticles carry-
ing the anticancer agent methotrexate (Hung et al 1990) 
by in situ polymerization of polyglutaraldehyde. Metho-
trexate is used in the treatment of various solid tumors. 
Their results demonstrated that the magnetic nanoparticles 
contained about 8% (w/w) of Fe3O4 and the drug loading 
rates varied between 40 to 94 μg per mg of nanoparticles. 
In conclusion, the authors suppose that these magnetic 
nanoparticles may offer active drug targeting for cancer 
chemotherapy, but it should be necessary to increase the 
entrapment of magnetite to allow efﬁ  cient retention of the 
carrier at the target site.
More recently, Arias reported a method to prepare 
colloidal composite particles consisting of a magnetite 
core and a biodegradable polymeric shell of poly(ethyl-
2-cyanoacrylate) by anionic polymerization (Arias et al 
2001). Despite the fact that the polyalkylcyanoacrylate 
family is considered of high interest as polymeric substrate 
in the realization of injectable nanoparticulate delivery 
systems (because of their mechanical properties, biodegrad-
ability and biocompatibility), their biodegradation products 
may be more toxic than those of other biodegradable/bio-
compatible polymers. 
Figure 4 Diagram of surface properties of iron oxide nanoparticles. Insert: surface silanization.
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In 1999, Zaitsev synthesized stable polymer coated mag-
netite nanoparticles by seed precipitation polymerization 
of methacrylic acid and hydroxyethyl methacrylate in the 
presence of nanophase magnetite (Zaitsev et al 1999). Deng 
described the preparation of magnetic polymeric particles 
via inverse microemulsion polymerization using acrylamide 
as water-soluble monomer (Deng et al 2003). They obtained 
water-dispersible magnetic polymeric nanoparticles with a 
size ranging from 80 to 180 nm. According to the authors, the 
magnetite concentrations in polymer particles were between 5% 
and 23% (w/w). However, the way in which magnetite content 
was determined from the values of saturation magnetization 
is not detailed.
Another polymer useful for encapsulation of magnetite 
particles is biodegradable poly(D,L-lactide) (PLA). This 
completely amorphous polymer is widely used in medical 
and pharmaceutical applications due to its very low toxicity 
and immunological response (Visscher et al 1985). 
Müller described coating magnetite nanoparticles with 
polylactide and polylactide/glycolide (PLA and PLAGA) by 
introducing under stirring an ethanolic magnetite dispersion 
into the melted polymers (Müller et al 1996). After solidi-
ﬁ  cation, the mass was ground to reduce the particle size to 
570 nm. The relatively low cytotoxicity of these magnetite-
loaded PLA and PLAGA nanoparticles was demonstrated in 
vitro on human granulocytes.
Gomez-Lopera prepared PLA-magnetite composite 
nanoparticles using big magnetite crystals with a size of 
about 160 nm (Gomez-Lopera et al 2001). The average 
diameter of coated particles was 180 nm. It seems possible 
that in this case the coverage of magnetite by PLA was very 
thin and incomplete. Thereafter, much interest has been 
focused on the use of composite nanoparticles prepared 
with poly(D,L-lactide-co-glycolide) (PLGA) polymer. 
The degradation of this FDA-approved polymer could be 
controlled by molecular weight, crystallinity and the ratio 
of lactide to glycolide. 
One of the technical limitations with hydrophobic polymers 
like PLA or PLGA is the difﬁ  culty to entrap high concentra-
tions of hydrophilic ferroﬂ  uids. To circumvent this problem, 
our group has modiﬁ  ed the surface of magnetite nanoparticles 
by adsorption of oleic acid before encapsulation in PLGA 
by a modiﬁ  ed solvent emulsiﬁ  cation/evaporation technique 
(Ngaboni Okassa et al 2005). This allowed the magnetite en-
capsulation efﬁ  ciency to be increased up to 60%. Nevertheless, 
the magnetite loading was rather low – about 1% (w/w) – and 
should be increased. The composite nanoparticles were found 
to have a mean diameter within the range of 270–370 nm.
At the same time, Lee prepared magnetic poly(D,L-
lactide-co-glycolide) nanoparticles by an emulsiﬁ  cation-
diffusion method (Lee et al 2005). Iron oxide nanoparticles 
(8–20 nm) were embedded in the PLGA matrix and 
the resulting iron oxide nanoparticles encapsulated have a 
size varying from 90 to 180 nm. Magnetic susceptibility of 
these nanoformulations increased as their size decreased. 
This was apparently related to the volume fraction of mag-
netic nanoparticles which increases when the size of the ﬁ  nal 
particles decreases. Unfortunately, no indication was given 
on the iron oxide content. 
Asmatulu reported model studies on magnetic control 
of magnetite nanoparticles embedded in poly(L-lactide), 
poly(D,L-lactide) and poly(ε−caprolactone) (Asmatulu et al 
2005). The magnetic retention of composite nanoparticles 
in a ﬂ  exible tube was measured as a function of various 
parameters such as magnetic saturation, magnet distance, 
ﬂ  uid speed, particle size and solid content. All these param-
eters were proven to inﬂ  uence the capture of the magnetic 
particles by an external magnetic ﬁ  eld but, unfortunately, no 
indication was given on the range of values needed to attain 
this objective in vivo. 
Although biocompatible, PLA or PLGA coating is not 
furtive because of its hydrophobic surface. Therefore, to 
obtain furtive nanovectors, the PLGA particles need an 
additional surface treatment with hydrophilic polymers. This 
remark leads one to the necessity to develop protocols of 
chemical bonding of hydrophilic polymers to the nanoparticle 
surface. In fact, such bonding can also be applied directly to 
iron oxide nanoparticles.
Treatment of the iron oxide surface 
for enhanced furtivity and reduced 
agglomeration
PEG-modiﬁ  ed iron oxide nanoparticles
To increase both the stability and furtivity of magnetic 
suspensions, iron oxide nanoparticles are often coated with 
hydrophilic polymers adsorbed or chemically attached to 
their surface. Polyethylene glycol (PEG) seems to be one 
of the most appropriate ones because of its unique proper-
ties such as hydrophilicity, ﬂ  exibility, nontoxicity, and non 
immunogenicity. 
Data from physico-chemical characterization indicate 
that coating with PEG efficiently reduces nanoparticle 
agglomeration (Gupta and Gupta 2005). A ﬁ  rst study to show 
that polyethylene oxide exhibits low protein adsorption was 
performed by Jeon and Andrade (Jeon and Andrade 1991). International Journal of Nanomedicine 2007:2(4) 547
Magnetic nanoparticular vectors of anticancer drugs
Consecutively to this study, many authors tried to link such 
polymers to the surface of different kinds of nanoparticles 
with the hope to decrease their uptake by the mononuclear 
phagocyte system (Storm et al 1995). 
Zhang et al (2002) immobilized silane-modiﬁ  ed PEG 
on the surface of magnetite nanoparticles. A rather similar 
approach for coating PEG to magnetic nanoparticles was 
proposed by Butterworth et al (2001). 
Using ﬂ  uorimetry, confocal ﬂ  uorescence microscopy and 
inductively coupled plasma emission spectroscopy (ICP), 
Zhang et al (2002) measured the uptake of their magnetic 
nanoformulations in breast cancer cells (BT20cells) and in 
mouse macrophage cells (RAW 264.7). The results of this 
study suggest that PEG coating of iron oxide nanoparticles 
limits protein adsorption on their surface and avoids their 
recognition by macrophages. Furthermore, PEG-modiﬁ  ed 
surfaces facilitate incorporation of nanoparticles by cancer 
cells, probably due to a high afﬁ  nity of the polymer to cel-
lular membranes. 
The main difﬁ  culty with using PEG for the formulation 
of nanovectors is that, except for the terminal (hydroxyl) 
group, this long-chain polymer lacks functional groups useful 
to attach therapeutic agents and/or speciﬁ  c ligands. Zhang 
circumvented this difﬁ  culty by introducing PEG modiﬁ  ed 
with a triﬂ  uoroethylester-silane terminus (Kohler et al 2004). 
This modiﬁ  cation allowed them to bind a folic acid ligand to 
PEG-treated magnetic nanoparticles. Since folate receptors 
are overexpressed on membranes of many cancer cells, the 
folic acid ligand should provide better access of nanovec-
tors to tumors. In this way, the targeting efﬁ  cacy should be 
additionally increased because the therapeutic vectors will be 
retained by both the recognition of a ligand and the magnetic 
ﬁ  eld. As interesting as this strategy is, it seems to be less 
appropriate for grafting an anticancer agent, because it will 
provide limited drug loading rates. 
Gupta also studied iron oxide nanoparticles modiﬁ  ed with 
PEG and found them to be internalized within lysosomes of 
ﬁ  broblasts (Gupta and Curtis 2004). In a different way, Acar 
covered iron oxide nanoparticles with PEGylated polymers 
(Acar et al 2005). In that case, the coating consisted of two 
layers, the inner layer consisting of an ionic surfactant such 
as 10-undecenoic acid, and the outer layer made of PEG 
modiﬁ  ed by esteriﬁ  cation with the same surfactant. These 
particles were synthesized according to various modes of 
preparation and present really interesting sizes for a possible 
administration in vivo. Furthermore, this way of synthesis 
offers interesting perspectives for ﬁ  xation of various water-
soluble polymers.
Polysaccharide-modiﬁ  ed iron oxide 
nanoparticles
As an alternative to PEG, natural polymers such as dextran, 
chitosan or starch can be attached to the surface of iron 
oxide nanoparticles in order to minimize the adsorption of 
proteins and to protect them from macrophages (Gupta and 
Gupta 2005). Dextran is a polymer of anhydroglucose having 
mainly alpha-D(1-6) linkages with side chains attached to the 
3-positions of the backbone glucose units. A little more than 
twenty years ago, Molday and Mackenzie prepared iron oxide 
nanoparticles modiﬁ  ed with dextran (Molday and Mackenzie 
1982). They mixed a solution of ferrous chloride and ferric 
chloride with dextran under alkaline conditions. Similar 
preparations, where dextran was physically adsorbed, were 
then studied by various authors (Pardoe et al 2001; Bautista 
et al 2005). Recently, Xu et al (2005) contributed to optimize 
the protocol by their study of various operating conditions. 
The authors reported that reaction time and size of the polymer 
are the main parameters essential for the quality of prepara-
tions. The high biological tolerance (Lacava et al 2004) of 
these modiﬁ  ed particles has been demonstrated and justiﬁ  ed 
their extensive use as contrast agents for magnetic-resonance 
imaging (MRI).
Incorporation of anticancer 
therapeutic agents in magnetic 
nanoformulations
The challenges described in this section are among the more 
difﬁ  cult and important to resolve. The association of drugs 
with nanovectors implies three main requirements. Firstly, 
the drug loading should be realistic to generate efﬁ  cient 
therapeutic concentrations. Secondly, the drug-nanovector 
association should be reversible and have no consequences 
on biological activity of the therapeutical agent. Finally, the 
drug release proﬁ  les should be compatible with a reasonable 
duration of the treatment.
Encapsulation of the drug
The association could be realized by physical encapsula-
tion of both drug and magnetic particles in a polymer 
matrix. In this case, the release of the drug will depend on 
the degradation or swelling of the polymer in the body. 
Although this approach is widely used to include active 
molecules in polymers (Puisieux et al 1994), only a few 
groups have combined these polymers simultaneously with 
drugs and magnetic materials (Ibrahim et al 1982; Hung 
et al 1990).International Journal of Nanomedicine 2007:2(4) 548
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Chemical binding of the drug
Alternatively, the drug can be incorporated into magnetic 
nanoformulations through chemical bonds with the iron 
oxide surface or the polymer coating. Many authors 
described the conjugation of anticancerous agents with 
a polymer in the absence of iron oxides. The idea was 
to use macromolecules as carriers for anticancer drugs 
mainly to improve their biodistribution and resistance to 
degradation and thus prolong their activity (reviewed in 
Kopecek et al 2000). As above, this type of drug charged 
polymer could one day be applied to the concept of mag-
netic drug targeting.
Ionic binding of the drug to magnetic nanoparticles
As an example where the drug is attached to the polymer 
by ionic attraction, one can cite nanoparticles loaded with 
epirubicin anticancer drug via interaction of its amino sugar 
with the anionic group of a modiﬁ  ed polymer (Bergemann 
et al 1999). This nanoformulation was used in the clinical 
trials described above (Lübbe, Bergemann, Riess et al 1996). 
Following the success of the ﬁ  rst clinical trials, the authors 
continued to study conditions of the drug release, distribu-
tion and mechanism of action both in vivo and in vitro. On 
the basis of commercial iron oxide nanoparticles, the same 
group developed a novel nanoformulation covered with 
modiﬁ  ed starch to which the therapeutic agent mitoxantrone 
was ionically bound (Alexiou et al 2001). Mitoxantrone 
is used in the treatment of a wide spectrum of tumors. To 
this end, the polymer must be initially functionalized by 
introducing for example anionic phosphate groups. An 
enormous advantage of this protocol is that it allows one to 
bind to the nanoparticles very different organic molecules, 
as long as they possess positively charged groups. Under 
physiologically relevant conditions in vitro, mitoxantrone 
was released from the magnetic nanoparticles in less than 
one hour. Biodistribution and activity in vivo of this nano-
formulation was assessed via the detection of mitoxantrone 
and of the nanoparticles (labeled with 59Fe and 123I) in tumors 
and in neighboring zones and organs (Alexiou et al 2003). 
Suspensions of nanovectors were injected intra-arterially for 
treatment of VX2 squamous cell carcinoma in rabbits, with 
only 50% of the usual systemic dose (Alexiou et al 2005). 
A magnetic ﬁ  eld was applied over the tumor for a duration 
of one hour. In comparison to control experiments without 
magnetic retention, the drug concentrations obtained in 
tumors under magnetic ﬁ  eld were largely higher and could 
explain remissions observed in spite of the lower amount 
of drug administered.
Covalent binding of the drug to magnetic 
nanoparticles
As described above, the main inconvenient of ionic binding 
is that the drug release depends on physiological parameters. 
To prevent this, another strategy is to couple the drug via 
a covalent bond to the iron oxide surface or to the polymer 
coating. The more current coupling agent for covalent bind-
ing directly to the iron oxide surface is aminopropylsilane 
(Kobayashi and Matsunaga 1991; Xu et al 1997, 1999; Zhang 
et al 2002). Aminopropylsilane presents the advantage to pos-
sess a reactive primary amino group that reacts for example 
as well with an aldehyde group to form a Schiff base as with 
a carboxylic acid group to form a peptide bond. For many 
years, proteins have been extensively immobilized on inor-
ganic supports such as magnetite via silane coupling agents 
(Weetall 1993). This methodology has then been applied to 
grafting drugs and/or polymers on iron oxide nanoparticles, 
one of the best examples being the study of Zhang (2002) 
described above. 
Recently, Kohler bound methotrexate via this method 
(Kohler et al 2005). Methotrexate has structural similarity 
with folic acid. This similarity could be favorable to the 
internalization of methotrexate by cancer cells. Magnetic 
nanoforms of methotrexate reduced the viability of human 
cervical cancer cells (Hela cell line), as well as that of human 
breast cancer cells (MCF-7 cell line) in culture. Cellular 
uptake of the nanovectors in these cells was observed by TEM 
and quantiﬁ  ed through measurement of iron concentrations 
by ICP. The data indicated that the vectors were accumulated 
into the lysosomes, where proteases should be able to cleave 
the amide bond between the drug and the magnetic particle. 
In fact, release of methotrexate in the presence of proteases 
was demonstrated in vitro (Kohler et al 2005). Internalization 
of the nanovectors and lysosomal release of the drug were 
presented as promising parameters for anticancer activity.
The necessity of internalization of the whole vector par-
ticles will depend on the general strategy adopted for the drug 
delivery. If the drug is covalently bound and needs speciﬁ  c 
enzymes or lower pH in lysosomes to trigger drug release, 
the whole particles have to enter the cell. Otherwise, simple 
diffusion through the polymer may be sufﬁ  cient to desorb 
the drug from the particle. Thus, cellular uptake of magnetic 
nanovectors is not a necessary condition for their anticancer 
activity. Indeed, nanovectors could stimulate drug uptake by 
cancer cells by locally providing high extracellular concentra-
tions of the drug and/or by direct action on the permeability 
of cellular membranes (Hong et al 2006). From this point 
of view, drug release from nanovectors in close vicinity of International Journal of Nanomedicine 2007:2(4) 549
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cancer cells could be sufﬁ  cient to bring a real advance in 
efﬁ  cacy of cancer chemotherapy.  
Final remarks
Magnetic drug targeting is a novel drug delivery system that 
has been proven feasible resulting in an increase in local 
drug concentration and thus permitting a reduction of side 
effects. Nevertheless, the clinical trials highlight numerous 
problems still to be resolved. If the principle of magnetic 
drug targeting is simple, the development of magnetic 
vectors is complex. The critical parameters to optimize are 
size, magnetization, biocompatibility, and drug loading and 
release. Although for the time being no preparation satis-
ﬁ  es all requirements simultaneously, most research groups 
succeed to produce biocompatible magnetic vectors with 
controllable sizes in the nanometer range. This is a source 
of optimism for a real possibility of magnetically targeted 
chemotherapy.
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